Sabatine, Marc S.

Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis

Giugliano, R. P., Pedersen, T. R., Saver, J. L., Sever, P. S., Keech, A. C., Bohula, E. A., Murphy, S. A., Wasserman, S. M., Honarpour, N., Wang, H., et al. (2020) · Stroke

Lipoproteins and Cardiovascular HealthAcute Ischemic Stroke Management

Cited by 184

Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study

Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., & Braunwald, E. (2006) · Journal of the American College of Cardiology

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 181

Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial

Sabatine, M. S., Giugliano, R. P., Keech, A., Honarpour, N., Wang, H., Liu, T., Wasserman, S. M., Scott, R., Sever, P. S., & Pedersen, T. R. (2016) · American Heart Journal

Lipoproteins and Cardiovascular HealthAcute Myocardial Infarction Research

Cited by 176

Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF

Jackson, A. M., Dewan, P., Anand, I. S., Bělohlávek, J., Bengtsson, O., de Boer, R. A., Böhm, M., Boulton, D. W., Chopra, V. K., DeMets, D. L., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 175

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., et al. (2019) · The Lancet Diabetes & Endocrinology

Bone health and osteoporosis researchMenopause: Health Impacts and Treatments

Cited by 169

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Bohula, E. A., Bonaca, M. P., Braunwald, E., Aylward, P. E., Corbalan, R., De Ferrari, G. M., He, P., Lewis, B. S., Merlini, P. A., Murphy, S. A., et al. (2016) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 168

Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

Reith, C., Preiss, D., Blackwell, L., Emberson, J., Spata, E., Davies, K., Halls, H., Harper, C., Holland, L., Wilson, K., et al. (2024) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 161

Heart failure risk stratification and efficacy of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes mellitus

Berg, D. D., Wiviott, S. D., Scirica, B. M., Gurmu, Y., Mosenzon, O., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 154

Comparison of Low-Density Lipoprotein Cholesterol Assessment by Martin/Hopkins Estimation, Friedewald Estimation, and Preparative Ultracentrifugation: Insights From the FOURIER Trial

Martin, S. S., Giugliano, R. P., Murphy, S. A., Wasserman, S. M., Stein, E. A., Ceška, R., López-Miranda, J., Georgiev, B., Lorenzatti, A. J., Tikkanen, M. J., et al. (2018) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 150

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Serenelli, M., Böhm, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., et al. (2020) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 138

An exploratory analysis of proprotein convertase subtilisin/kexin type 9 inhibition and aortic stenosis in the FOURIER trial

Bergmark, B. A., O’Donoghue, M. L., Murphy, S. A., Kuder, J. F., Ezhov, M. V., Ceška, R., Gouni-Berthold, I., Jensen, H. K., Tokgozoglu, S. L., Mach, F., et al. (2020) · JAMA Cardiology

Lipoproteins and Cardiovascular HealthCardiac Valve Diseases and Treatments

Cited by 137

Efficacy and safety of evolocumab (AMG 145), a fully human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials

Stein, E. A., Giugliano, R. P., Koren, M. J., Raal, F. J., Roth, E. M., Weiss, R., Sullivan, D., Wasserman, S. M., Somaratne, R., Kim, J. B., et al. (2014) · European Heart Journal

Lipoproteins and Cardiovascular HealthLipid metabolism and disorders

Cited by 130

The effect of dapagliflozin on albuminuria in DECLARE-TIMI 58

Mosenzon, O., Wiviott, S. D., Heerspink, H. J. L., Dwyer, J. P., Cahn, A., Goodrich, E. L., Rozenberg, A., Schechter, M., Yanuv, I., Murphy, S. A., et al. (2021) · Diabetes Care

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 113

An Invasive or Conservative Strategy in Patients With Diabetes Mellitus and Non–ST-Segment Elevation Acute Coronary Syndromes

O'Donoghue, M. L., Vaidya, A., Afsal, R., Alfredsson, J., Boden, W. E., Braunwald, E., Cannon, C. P., Clayton, T. C., de Winter, R. J., Fox, K. A. A., et al. (2012) · Journal of the American College of Cardiology

Coronary Interventions and DiagnosticsAcute Myocardial Infarction Research

Cited by 106

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial

Ruff, C. T., Baron, M., Im, K., O’Donoghue, M. L., Fiedorek, F. T., & Sabatine, M. S. (2022) · Nature Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 102

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Targeting APOC3 with Olezarsen in Moderate Hypertriglyceridemia

Bergmark, B. A., Marston, N. A., Prohaska, T. A., Alexander, V. J., Zimerman, A., Moura, F. A., Kang, Y. M., Weinland, J., Murphy, S. A., Goodrich, E. L., et al. (2025) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 78

Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk

Marston, N. A., Bergmark, B. A., Alexander, V. J., Prohaska, T. A., Kang, Y. M., Moura, F. A., Zimerman, A., Waldman, E., Weinland, J., Murphy, S. A., et al. (2026) · New England Journal of Medicine

Lipid metabolism and disordersLipoproteins and Cardiovascular Health

Cited by 62

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial

Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 52

Effect of dapagliflozin in DAPA-HF according to background glucose-lowering therapy

Docherty, K. F., Jhund, P. S., Bengtsson, O., DeMets, D. L., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Langkilde, A. M., Martinez, F. A., Sabatine, M. S., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 44

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41

Plasma Omega-3 Fatty Acids and the Risk of Cardiovascular Events in Patients after an Acute Coronary Syndrome in MERLIN-TIMI 36

Zelniker, T. A., Morrow, D. A., Scirica, B. M., Furtado, J. D., Guo, J., Mozaffarian, D., Sabatine, M. S., & O’Donoghue, M. L. (2021) · Journal of the American Heart Association

Fatty Acid Research and HealthAcute Myocardial Infarction Research

Cited by 26

Novel Polygenic Risk Score and Established Clinical Risk Factors for Risk Estimation of Aortic Stenosis

Small, A. M., Melloni, G. E. M., Kamanu, F. K., Bergmark, B. A., Bonaca, M. P., O’Donoghue, M. L., Giugliano, R. P., Scirica, B. M., Bhatt, D., Antman, E. M., et al. (2024) · JAMA Cardiology

Cardiac Valve Diseases and TreatmentsGenetic Associations and Epidemiology

Cited by 23

Genomic and transcriptomic analyses of aortic stenosis enhance therapeutic target discovery and disease prediction

Small, A. M., Yang, T.-Y., Itoh, S., Thériault, S., Dufresne, L., Kurosawa, R., Komuro, I., Matsuda, K., Vy, H. M. T., Farber-Eger, E. H., et al. (2026) · Nature Genetics

Cardiac Valve Diseases and TreatmentsGenetic Associations and Epidemiology

Cited by 18